Sign In
Buy VRTX
$428.34
+3.25 (+0.765%)
At Close: Jun 03, 2026
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRTX)
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
10:01am, Wednesday, 01'st Jan 2025
Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Vertex Pharmaceuticals (VRTX) Advances While Market Declines: Some Information for Investors
07:20pm, Tuesday, 31'st Dec 2024
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $402.70, marking a +0.84% move from the previous day.
Vertex Pharmaceuticals: Jim Cramer Fires A Warning Shot But I Remain Invested
09:02am, Tuesday, 31'st Dec 2024
Vertex Pharmaceuticals' suzetrigine showed lackluster Phase II results, but I still see potential in the non-addictive pain management market given the opioid crisis. Vertex's dominance in the cystic
NEW YORK, NY / ACCESSWIRE / December 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
Is the Options Market Predicting a Spike in Vertex Pharmaceuticals (VRTX) Stock?
09:30am, Monday, 30'th Dec 2024
Investors need to pay close attention to Vertex Pharmaceuticals (VRTX) stock based on the movements in the options market lately.
Vertex Pharmaceuticals Incorporated (VRTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates
07:25am, Monday, 30'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
08:00am, Saturday, 28'th Dec 2024
Every investor has heard the phrase "buy low, sell high." It's a simple enough piece of advice that's less simple to apply.
NEW YORK, NY / ACCESSWIRE / December 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
08:30am, Thursday, 26'th Dec 2024
Vertex Pharmaceuticals (VRTX 0.72%) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to doubt
NEW YORK, NY / ACCESSWIRE / December 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex Pharmaceuticals Incorporated ("Vertex Pharmaceuticals") (NASDAQ:VRT
3 No-Brainer Stocks to Buy on the Latest Sell-Off
05:25am, Tuesday, 24'th Dec 2024
Warren Buffett's mentor Benjamin Graham once said, "In the short run, the market is a voting machine but in the long run, it is a weighing machine." He understood that stocks are largely driven by inv
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
04:05pm, Monday, 23'rd Dec 2024
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Mor
Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman
03:45pm, Monday, 23'rd Dec 2024
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025.
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
02:46pm, Monday, 23'rd Dec 2024
The FDA's nod is based on late-stage data, which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta.
